Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$555M |
| 2 |
Citigroup
C
|
+$407M |
| 3 |
Medtronic
MDT
|
+$401M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$392M |
| 5 |
Gilead Sciences
GILD
|
+$362M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.43B |
| 2 |
Amazon
AMZN
|
+$1.32B |
| 3 |
Apple
AAPL
|
+$1.1B |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$995M |
| 5 |
Bank of America
BAC
|
+$726M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 83.47% |
| 2 | Technology | 3.02% |
| 3 | Healthcare | 2.92% |
| 4 | Consumer Discretionary | 2.17% |
| 5 | Financials | 2.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
13001
PUT
State Street SPDR Nuveen ICE High Yield Municipal Bond ETF
HYMB
$3.71B
| $13.1K | ﹤0.01% |
+500
| New | +$13K |
2024 Q3
0 quarters
|
|
|
FFIC
13002
PUT
DELISTED
Flushing Financial
FFIC
| $13.1K | ﹤0.01% |
900
+700
| +350% | +$9.85K |
2023 Q4
3 quarters
|
|
13003
PUT
Vera Bradley
VRA
$144M
| $13.1K | ﹤0.01% |
2,400
-1,900
| -44% | -$11.2K |
2023 Q4
3 quarters
|
|
13004
PUT
Atossa Therapeutics
ATOS
$24.4M
| $13.1K | ﹤0.01% |
573
-527
| -48% | -$10.6K |
2020 Q2
17 quarters
|
|
13005
CALL
Fate Therapeutics
FATE
$291M
| $12.9K | ﹤0.01% |
3,700
+600
| +19% | +$2.33K |
2018 Q2
25 quarters
|
|
13006
CALL
CareCloud
CCLD
$86.7M
| $12.9K | ﹤0.01% |
4,900
+2,900
| +145% | +$6.93K |
2024 Q1
2 quarters
|
|
13007
PUT
Simmons First National
SFNC
$3.28B
| $12.9K | ﹤0.01% |
600
+300
| +100% | +$6.09K |
2023 Q1
6 quarters
|
|
13008
PUT
ESCO Technologies
ESE
$7.04B
| $12.9K | ﹤0.01% |
100
| – | – |
2024 Q1
2 quarters
|
|
13009
CALL
China Automotive Systems
CAAS
$142M
| $12.9K | ﹤0.01% |
2,800
+2,500
| +833% | +$9.35K |
2022 Q3
8 quarters
|
|
13010
CALL
iShares US Broker-Dealers & Securities Exchanges ETF
IAI
$1.33B
| $12.9K | ﹤0.01% |
+100
| New | +$12.4K |
2024 Q3
0 quarters
|
|
13011
PUT
Vanguard Morningstar Mega Cap Value ETF
MGV
$13.3B
| $12.8K | ﹤0.01% |
100
-300
| -75% | -$37K |
2024 Q2
1 quarter
|
|
13012
PUT
VOC Energy
VOC
$58.1M
| $12.8K | ﹤0.01% |
2,600
-10,300
| -80% | -$51.2K |
2022 Q4
7 quarters
|
|
13013
PUT
Enliven Therapeutics
ELVN
$3.33B
| $12.8K | ﹤0.01% |
500
-100
| -17% | -$2.32K |
2024 Q2
1 quarter
|
|
13014
PUT
ALX Oncology
ALXO
$167M
| $12.7K | ﹤0.01% |
7,000
-29,600
| -81% | -$110K |
2022 Q4
7 quarters
|
|
|
LAZR
13015
DELISTED
Luminar Technologies
LAZR
| $12.7K | ﹤0.01% |
944
| – | – |
2024 Q1
2 quarters
|
|
13016
CALL
InfuSystem Holdings
INFU
$269M
| $12.7K | ﹤0.01% |
1,900
+400
| +27% | +$2.59K |
2022 Q4
7 quarters
|
|
13017
60 Degrees Pharmaceuticals
SXTP
$5.06M
| $12.7K | ﹤0.01% |
+505
| New | +$18.7K |
2024 Q3
0 quarters
|
|
|
GIPRW
13018
DELISTED
Generation Income Properties Inc Warrant
GIPRW
| $12.7K | ﹤0.01% |
42,274
+339
| +0.8% | +$125 |
2023 Q3
4 quarters
|
|
13019
CALL
Energy Vault
NRGV
$704M
| $12.7K | ﹤0.01% |
13,200
+11,700
| +780% | +$11.8K |
2024 Q2
1 quarter
|
|
13020
CALL
BGSF Inc
BGSF
$51M
| $12.6K | ﹤0.01% |
1,500
-200
| -12% | -$1.61K |
2024 Q2
1 quarter
|
|
|
NAK
13021
CALL
Northern Dynasty Minerals
NAK
$731M
| $12.6K | ﹤0.01% |
38,100
+12,600
| +49% | +$4.42K |
2017 Q1
30 quarters
|
|
|
CAPT
13022
DELISTED
Captivision
CAPT
| $12.6K | ﹤0.01% |
+6,377
| New | +$13.9K |
2024 Q3
0 quarters
|
|
|
CLLS
13023
CALL
Cellectis
CLLS
$142M
| $12.6K | ﹤0.01% |
5,900
+3,100
| +111% | +$6.73K |
2024 Q2
1 quarter
|
|
13024
PUT
ProShares UltraShort MSCI Brazil Capped
BZQ
$1.89M
| $12.6K | ﹤0.01% |
+250
| New | +$13.3K |
2024 Q3
0 quarters
|
|
13025
PUT
MediciNova
MNOV
$86.1M
| $12.6K | ﹤0.01% |
6,000
+2,200
| +58% | +$3.25K |
2024 Q1
2 quarters
|
|
Similar funds
Citadel Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Citadel Advisors held 15,731 positions worth $518B, up 4.9% from $494B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Citadel Advisors's Q3 2024 filing shows 1,612 new, 6,434 increased, 5,866 reduced and 1,610 closed positions. Its largest new stake was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M. The largest sale was Invesco QQQ Trust, an estimated $1.43B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, up from 82% a quarter earlier, followed by Technology and Healthcare.
- Citadel Advisors's largest Q3 2024 buy was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M.
- Citadel Advisors added most to NVIDIA in Q3 2024, an estimated $555M increase.
- Citadel Advisors's biggest Q3 2024 reduction was Invesco QQQ Trust, cutting an estimated $1.43B.
- Citadel Advisors fully exited Domino's in Q3 2024, selling an estimated $186M.
- Citadel Advisors's ten largest holdings make up 30% of its $518B portfolio in Q3 2024.
- Citadel Advisors opened 1,612 new positions and closed 1,610 in Q3 2024.
- Citadel Advisors's portfolio value rose 4.9% quarter-over-quarter to $518B.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.